Biosimilar Market Growth to 2021 Driven by US, Europe and Japan

News provided by

Oct 28, 2015, 12:45 ET

PUNE, India, October 28, 2015 /PRNewswire/ --

This global and USA biosimilar market report for 2015 to 2021 says that in order to gain a slice of the $190 billion worth of biologic's market, many biotechnology companies have ventured into the biosimilar sector bringing out less-expensive copies of reference biologics.

Complete report on biosimilar market spread across 271 pages, profiling 90+ companies and supported with 134 tables and 89 figures is now available at http://www.reportsnreports.com/reports/411918-global-usa-biosimilar-market-analysis-to-2021-biobetters-erythropoietin-epo-human-growth-hormone-hgh-granulocyte-colony-stimulating-factor-g-csf.html .

This report provides a comprehensive overview of the size of biosimilar market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. On total, about 44 biosimilars are available in the global market and currently the E.U. is the major market with 19 approved biosimilars in use. A significant number of biosimilars are available in the markets of China, India, South Korea and Latin America. Biosimilars from these emerging countries are approved by a less-stringent approval pathway and therefore, the commercialization of their products is mostly confined to the domestic markets. This biosimilar market report describes how the long-awaited FDA approval of Zarxio from Sandoz (biosimilar for Amgen's Neupogen) in March 2015 is to transform the otherwise nascent market.

The 2015-2021 biosimilar market report includes an overview of biosimilars that includes differences between biologics; biosimilars and generics, definition of biosimilars by different agencies, barriers in developing biosimilars, cost of developing biosimilars. It presents a summary of regulatory pathways in various geographic regions, development of biosimilars in Europe, China, India, South Korea, Latin America and the sudden spurt in the development of biosimilars in the U.S. as well as a list of biosimilar developers in different geographic locations. An overview of biobetters that includes regulatory considerations, differences between biosimilars and biobetters, various biobetters that are in developmental stages, and the companies with the largest biobetter pipeline is provided along with an overview of approved biosimilars in the E.U., U.S., India, South Korea and Latin America.

The impact of biosimilar market on their reference biologics such as Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus through 2021, top ten biologics on the focus of biosimilar developers, five major classes of biologics and their biosimilar counterparts, current landscape of originators of biosimilars, Global market for biologics by region, through 2021, by indication, by drug class, through 2021, Global market for biosimilars by region, through 2021, by indication, by drug class, through 2021, profiles of 95 biosimilar market developers, their products in the market and their product pipeline as well as a newsletter in the appendix gives the latest news of biosimilar sector as of February 2015 is covered in this research.

Order a copy of Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Outlook research report at http://www.reportsnreports.com/Purchase.aspx?name=411918 .

The second research titled New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan says 2015 will be a litmus test for the next five years cumulative ¥400b biosimilar opportunity in Japan and will give clarity on the importance of "Made in Japan" (Filgrastim biosimilar competition amongst six players) and "Tested by Japan" (NK's Remicade biosimilar) factor for biosimilar penetration. This report provides a crisp summery on activities and plans of ~19 Japanese companies venturing in bio-similar space and ~6 multi-national companies that are going to play important role in the space. Companies mentioned include JCR Pharma, Meiji Seika, Fuji Film Kyowa Kirin Biologics, Nichi-Iko, Mochida, Nipro Pharm, Yoshindo, Nippon Kayaku , Mitsubishi Tanabe, Sawa, Towa, Daiichi Sankyo, UMN Pharma, Kissei, Kyowa Hakko Kirin, Aska Pharma, Toyobo Biologics, Gene Techno Science. Read more at http://www.reportsnreports.com/reports/344228-new-phase-of-mab-biosimilar-knocks-the-door-biosimilar-oppurtunities-in-japan.html .

Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

Connect With Us on:

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports